Carisma Therapeutics, Inc. (CARM)

Market Cap	1.79M -90.7%
Revenue (ttm)	52.63M +159.7%
Net Income	8.04M
EPS	0.19
Shares Out	41.85M
PE Ratio	0.22
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,830
Average Volume	94,725
Open	0.0460
Previous Close	0.0418
Day's Range	0.0420 - 0.0460
52-Week Range	0.0261 - 1.2700
Beta	3.70
RSI	50.76
Earnings Date	Mar 31, 2026

About Carisma Therapeutics

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 46
• Stock Exchange: OTCMKTS
• Ticker Symbol: CARM

Financial Performance

In 2024, Carisma Therapeutics's revenue was $19.63 million, an increase of 31.59% compared to the previous year's $14.92 million. Losses were -$60.48 million, -30.39% less than in 2023.